Cellectis S.A. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma on August 15, 2027. There is 1 upcoming event on record.
Cash runway is approximately 13.4 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.